Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

About this update from Vortex Energy Corp.

[{"type":"text","content":"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n Vertex Pharmaceuticals Incorporated\n \n (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa.\n \n\n “For more than 20 years, Paul and the team of dedicated Vertex researchers have focused on discovering and developing breakthrough therapies for people living with cystic fibrosis (CF). Paul’s outstanding vision, leadership, determination and collaborative nature has resulted in what was once thought impossible — the discovery of the first-ever protein folding corrector medicines that treat the underlying cause of CF and have forever transformed the course of this disease,” said David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer at Vertex.\n \n\n “I am honored and humbled by this award that recognizes not only me, but also the dedication, creativity and scientific excellence of the thousands of people across Vertex, and in the CF community, who have been steadfast in their commitment to bringing these medicines to people with cystic fibrosis around the world,” said Negulescu.\n \n\n The gene responsible for CF was discovered in 1989, but until the work of Vertex scientists led by Negulescu, treatments for CF addressed only its symptoms rather than the underlying cause of disease. Today, Vertex’s five approved medicines treat CF by restoring function of the defective CFTR protein. The most recently approved medicine is a triple combination therapy that has the potential to treat more than 90% of people with CF with any of more than 300 different mutations, with once-daily dosing. The research team continues its relentless efforts to discover and develop even mor...

More updates from Vortex Energy Corp.